236 related articles for article (PubMed ID: 19247406)
41. Treatment of clinically organ confined prostate cancer.
McLeod DG
Scand J Urol Nephrol Suppl; 1999; 203():35-9. PubMed ID: 10636568
[No Abstract] [Full Text] [Related]
42. A new non-steroidal anti-androgen.
Denis L
Prog Clin Biol Res; 1989; 303():95-103. PubMed ID: 2675023
[No Abstract] [Full Text] [Related]
43. [Solitary peritoneal carcinomatosis in prostate cancer].
Brehmer B; Makris A; Wellmann A; Jakse G
Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
[TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
45. Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.
Kanesvaran R; Phipps C; Cheng CW; Chan MM; Khoo D; Tan MH
Ann Acad Med Singap; 2010 Jul; 39(7):580-2. PubMed ID: 20697679
[No Abstract] [Full Text] [Related]
46. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Lloyd A; Penson D; Dewilde S; Kleinman L
Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
[TBL] [Abstract][Full Text] [Related]
47. A case of male breast cancer in association with bicalutamide-induced gynaecomastia.
Chianakwalam CI; McCahy P; Griffiths NJ
Breast; 2005 Apr; 14(2):163-4. PubMed ID: 15767188
[No Abstract] [Full Text] [Related]
48. The role of anti-androgen monotherapy in the treatment of prostate cancer.
Bishop M
BJU Int; 2003 Oct; 92(6):653-4. PubMed ID: 14511060
[No Abstract] [Full Text] [Related]
49. Bicalutamide for prostate cancer.
Med Lett Drugs Ther; 1996 Jun; 38(977):56-7. PubMed ID: 8657047
[No Abstract] [Full Text] [Related]
50. Comment on "secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study".
de la Taille A
World J Urol; 2014 Dec; 32(6):1625-6. PubMed ID: 24413818
[No Abstract] [Full Text] [Related]
51. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
Morote J; Planas J; Salvador C; Raventós CX; Catalán R; Reventós J
BJU Int; 2009 Feb; 103(3):332-5; discussion 335. PubMed ID: 19007366
[TBL] [Abstract][Full Text] [Related]
52. [Neoadjuvant hormone therapy with casodex in a dose 150 mg prior to radical prostatectomy in patients with prostatic cancer].
Rusakov IG; Petrov SB; Alekseev BIa; Veliev EI
Urologiia; 2004; (4):15-9. PubMed ID: 15457946
[No Abstract] [Full Text] [Related]
53. Mixed acinar and macrocystic ductal prostatic adenocarcinoma.
Giganti F; Allen C; Sridhar A; Tandogdu Z; Ramachandran N; Dickinson L; Haider A; Freeman A; Ball R; Moore CM
Lancet Oncol; 2021 Jan; 22(1):e37. PubMed ID: 33387504
[No Abstract] [Full Text] [Related]
54. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
55. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
56. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
57. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
[TBL] [Abstract][Full Text] [Related]
58. Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer.
Anderson J
BJU Int; 2004 Oct; 94(6):758-9. PubMed ID: 15476502
[No Abstract] [Full Text] [Related]
59. Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases.
Yano A; Kagawa M; Takeshita H; Okada Y; Morozumi M; Kawakami S
Int J Urol; 2017 Dec; 24(12):861-862. PubMed ID: 28895205
[No Abstract] [Full Text] [Related]
60. Casodex--mechanisms of action and opportunities for usage.
Blackledge G
Cancer; 1993 Dec; 72(12 Suppl):3830-3. PubMed ID: 7504578
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
